Coronary disease & ACS

Sex-based differences in adverse left ventricular remodelling and clinical outcomes after ST-segment elevation myocardial infarction

Eur Heart J Cardiovasc ImagingPublished study

Main finding · Adverse LVR (>15% of LV end-diastolic volume and a decrease of >3% in LV ejection fraction)Result — go to the resultOdds ratio 0.80 95% CI 0.39–1.64

Authors' conclusion

The higher rate of MACE after STEMI in women compared to men appears to be associated with a higher prevalence of CVRF and comorbidities rather than a more significant occurrence of adverse LVR.

Study context

Population
Patients with a first ST-elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (PCI)17.5% women, mean age: 58.71 ± 11.85 years
Participants
1,067 patients
Comparison
Female vs male sex
Outcome
Adverse LVR (>15% of LV end-diastolic volume and a decrease of >3% in LV ejection fraction)
Follow-up
6 months

Main finding

As reported in the abstract

Odds ratio

0.80

95% CI 0.39–1.64

P = 0.536

Womenvs Men
OR 0.80 (95% CI 0.39–1.64); P = 0.536

Secondary outcomes

OutcomeWomenMenHazard ratio (95% CI)P value
MACE (cardiovascular death, heart failure admission, or ventricular arrhythmias) (secondary endpoint) · Follow-up 6.94 years (IQR: 4.48-9.32 years)After adjusting for baseline differences and CVRF22.6%15.4%1.21 (0.81–1.81)P = 0.343
MACE (cardiovascular death, heart failure admission, or ventricular arrhythmias) (secondary endpoint) — MACE overall
177 patients (16.7%)
  • MACE (cardiovascular death, heart failure admission, or ventricular arrhythmias) (secondary endpoint): unadjusted women vs men P = 0.017

Original publication

Sex-based differences in adverse left ventricular remodelling and clinical outcomes after ST-segment elevation myocardial infarction. Eur Heart J Cardiovasc Imaging. Published 10 February 2025. doi:10.1093/ehjci/jeaf048

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.